glp 1 studies 2025 How Pharmacy Plans Are Managing GLP-1 Coverage in GLP-1R Race in 2025: 8
Description
Interestingly, higher incidence of diabetic retinopathy (DR) complications was noted in patients taking semaglutide (3.0%) compared to placebo (1.5%) in clinical trials, with greater risk in those with a history of DR [32]
Consistent access to therapy is also essential, as interruptions can worsen GI symptoms and reduce adherence
When they stop taking the medication, theyre exposing their body to whiplash that stresses the heart and undoes a lot of those cardiovascular benefits, Dr
Insulin remains insulin
